Issues concerning prenatal screening and diagnosis of Down syndrome
Conseil d'Evaluation des Technologies de la Sante du Quebec
Record ID 32002000320
This report aims to assess whether it would be appropriate to introduce prenatal screening using maternal serum markers in Quebec.
Authors' recomendations: In conclusion, CETS considers that Down syndrome screening using serum markers should be made available to all pregnant women in Quebec, regardless of their age. Their participation should be voluntary and they should freely give their informed consent after receiving complete, high-quality information from the professionals involved. The best screening strategy is one that enables more cases of Down syndrome to be diagnosed with the lowest risk of iatrogenic fetal loss at an acceptable cost, and that respects existing rights with respect to amnicentesis as of age 35. It must also be readily adaptable to new technological developments.
Authors' methods: Cost study, Review
Project Status: Completed
URL for project: http://www.aetmis.gouv.qc.ca/
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Down Syndrome
- Mass Screening
- Prenatal Diagnosis
Organisation Name: Conseil d'Evaluation des Technologies de la Santé du Québec
Contact Address: Conseil d'Evaluation des Technologies de la Santé du Québec, 2021, avenue Union, #1040, Montréal, Québec H3A S29, Canada. Tel: 514-873-2563; FAX: 514-873-1369
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.